×
About 770 results

ALLMedicine™ Pustular Psoriasis Center

Research & Reviews  257 results

Case series show no consensus on treatment for palmoplantar pustulosis, generalized pustular psoriasis
https://www.mdedge.com/dermatology/article/250395/psoriasis/case-series-show-no-consensus-treatment-palmoplantar-pustulosis
Jeff Craven

Jan 4th, 2022 - A wide range of treatments are being used to manage patients with palmoplantar pustulosis (PPP) and generalized pustular psoriasis (GPP), according to the results of two case series that evaluated the characteristics and course of the disease in p.

Prevalence and incidence of generalised pustular psoriasis in Sweden - a population-bas...
https://doi.org/10.1111/bjd.20966
The British Journal of Dermatology; Löfvendahl S, Norlin JM et. al.

Jan 4th, 2022 - Generalised pustular psoriasis (GPP) is a severe form of pustular psoriasis with generalised eruption of sterile pustules, often along with systemic symptoms. There is a scarcity of population-based estimates of GPP prevalence and incidence. To es...

A Study of Guselkumab in Participants With Active Lupus Nephritis
https://clinicaltrials.gov/ct2/show/NCT04376827

Jan 3rd, 2022 - Guselkumab is a monoclonal antibody (mAb) that binds to human interleukin (IL)-23 with high affinity and blocks binding of extracellular IL-23 to cell surface IL-23 receptor, inhibiting IL 23 specific intracellular signaling and subsequent activat...

A Study to Evaluate Guselkumab for the Treatment of Participants With New-onset or Relapsing Giant Cell Arteritis
https://clinicaltrials.gov/ct2/show/NCT04633447

Jan 3rd, 2022 - Giant cell arteritis (GCA) is a non-necrotizing granulomatous systemic vasculitis of unknown etiology affecting medium-sized and large arteries usually accompanied or preceded by systemic inflammation. Guselkumab is a monoclonal antibody (mAb) tha...

Transcriptomes of MPO-deficient patients with generalized pustular psoriasis reveals ex...
https://doi.org/10.1016/j.jid.2021.12.021
The Journal of Investigative Dermatology; Haskamp S, Frey B et. al.

Jan 2nd, 2022 - Generalized pustular psoriasis (GPP) is a severe psoriatic subtype characterized by epidermal neutrophil infiltration. Although variants in IL36RN and MPO have been shown to affect immune cells, a systematic analysis of neutrophils and peripheral ...

see more →

Drugs  9 results see all →

Clinicaltrials.gov  10 results

A Study of Guselkumab in Participants With Active Lupus Nephritis
https://clinicaltrials.gov/ct2/show/NCT04376827

Jan 3rd, 2022 - Guselkumab is a monoclonal antibody (mAb) that binds to human interleukin (IL)-23 with high affinity and blocks binding of extracellular IL-23 to cell surface IL-23 receptor, inhibiting IL 23 specific intracellular signaling and subsequent activat...

A Study to Evaluate Guselkumab for the Treatment of Participants With New-onset or Relapsing Giant Cell Arteritis
https://clinicaltrials.gov/ct2/show/NCT04633447

Jan 3rd, 2022 - Giant cell arteritis (GCA) is a non-necrotizing granulomatous systemic vasculitis of unknown etiology affecting medium-sized and large arteries usually accompanied or preceded by systemic inflammation. Guselkumab is a monoclonal antibody (mAb) tha...

A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
https://clinicaltrials.gov/ct2/show/NCT03022045

Nov 18th, 2021 - Safety and efficacy data through 14 December 2017 are included in the interim analysis, which was conducted after all participants completed the Week 28 visit or discontinued from the study.

A Study to Evaluate the Efficacy and Safety of ANB019 in Subjects With Generalized Pustular Psoriasis
https://clinicaltrials.gov/ct2/show/NCT03619902

Oct 12th, 2021 - This is a Phase II single arm multiple dose study to assess the efficacy and safety, and PK of ANB019 in subjects with Generalized Pustular Psoriasis

A Phase 4 Clinical Study of Brodalumab
https://clinicaltrials.gov/ct2/show/NCT04183881

Dec 9th, 2019 - This study [4827-005 (post market)] is designed to evaluate the safety and efficacy of long-term exposure to brodalumab in subjects with plaque psoriasis (psoriasis vulgaris, psoriatic arthritis) who have completed Study 4827-003 (Study 003) and i...

see more →

News  30 results

Case series show no consensus on treatment for palmoplantar pustulosis, generalized pustular psoriasis
https://www.mdedge.com/dermatology/article/250395/psoriasis/case-series-show-no-consensus-treatment-palmoplantar-pustulosis
Jeff Craven

Jan 4th, 2022 - A wide range of treatments are being used to manage patients with palmoplantar pustulosis (PPP) and generalized pustular psoriasis (GPP), according to the results of two case series that evaluated the characteristics and course of the disease in p.

Case Series Show No Consensus on Treatment for Palmoplantar Pustulosis, Generalized Pustular Psoriasis
https://www.medscape.com/viewarticle/965994

Jan 4th, 2022 - A wide range of treatments are being used to manage patients with palmoplantar pustulosis (PPP) and generalized pustular psoriasis (GPP), according to the results of two case series that evaluated the characteristics and course of the disease in p...

Spesolimab speeds lesion clearance in generalized pustular psoriasis
https://www.mdedge.com/dermatology/article/250261/psoriasis/spesolimab-speeds-lesion-clearance-generalized-pustular
Heidi Splete

Dec 27th, 2021 - Spesolimab, a humanized, anti–interleukin-36 receptor monoclonal antibody, was associated with rapid improvement in pustules during flares, in a phase 2 study of 53 adults with generalized pustular psoriasis (GPP). GPP is a life-threatening skin c.

Spesolimab Speeds Lesion Clearance in Generalized Pustular Psoriasis
https://www.medscape.com/viewarticle/965608

Dec 27th, 2021 - Spesolimab, a humanized, anti–interleukin-36 receptor monoclonal antibody, was associated with rapid improvement in pustules during flares, in a phase 2 study of 53 adults with generalized pustular psoriasis (GPP). GPP is a life-threatening skin c...

Dramatic Improvement in Generalized Pustular Psoriasis With IL-36 Inhibitor
https://www.medpagetoday.com/dermatology/psoriasis/96365

Dec 23rd, 2021 - Patients with severe generalized pustular psoriasis (GPP) had rapid clearance of skin lesions when treated with an investigational interleukin (IL)-36 inhibitor, a small randomized trial showed. One week after treatment with intravenous spesolimab...

see more →

Patient Education  2 results see all →